{"id":2414,"date":"2025-01-14T10:59:40","date_gmt":"2025-01-14T07:59:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2414"},"modified":"2025-03-07T14:58:30","modified_gmt":"2025-03-07T11:58:30","slug":"edgewise-therapeutics-announces-plans-for-2025","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/edgewise-therapeutics-announces-plans-for-2025\/","title":{"rendered":"Edgewise Therapeutics annonce ses projets pour 2025"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder. [Read More: <a href=\"https:\/\/dmdwarrior.com\/differences-between-dmd-and-bmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Differences Between DMD and BMD?<\/a>]<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete recruitment of the GRAND CANYON pivotal placebo-controlled cohort in the first quarter of 2025<\/li>\n\n\n\n<li>Seek end of Phase 2 feedback from the U.S. Food and Drug Administration (FDA) on CANYON results for sevasemten in Becker in the first half of 2025<\/li>\n\n\n\n<li>Report data from the Phase 2 LYNX and FOX trials in the first half of 2025 and outline potential Phase 3 plans in individuals with Duchenne<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2417,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[67,66,151,152,150],"class_list":["post-2414","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-becker-muscular-dystrophy","tag-duchenne-muscular-dystrophy","tag-edgewise","tag-edgewise-therapeutics","tag-sevasemten"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2414"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2417"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}